View Older Stories View More Recent Stories
-
Sage Therapeutics (SAGE) PT Lowered to $8.50 at TD Cowen
-
Sage Therapeutics (SAGE) PT Raised at Truist; 'SAGE Acquisition A Good Outcome For All'
-
Piper Sandler Downgrades Sage Therapeutics (SAGE) to Neutral
-
Supernus Pharma (SUPN) to Acquire Sage Therapeutics (SAGE)
-
SAGE Therapeutics (SAGE) Misses Q1 EPS by 2c
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of Sage Therapeutics, Inc. (SAGE)
-
SAGE Therapeutics (SAGE) Announces R&D Leadership Transition
-
Sage Therapeutics (SAGE) PT Lowered to $12 at H.C. Wainwright
-
Sage Therapeutics (SAGE) PT Lowered to $8 at Canaccord Genuity
-
SAGE Therapeutics (SAGE) Misses Q4 EPS by 6c
-
Sage Therapeutics (SAGE) PT Raised to $9 at Mizuho
-
Sage Therapeutics (SAGE) Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s (BIIB) Unsolicited Acquisition Proposal
-
SAGE Therapeutics (SAGE) Explores Strategic Alternatives
-
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier)
-
SAGE Therapeutics (SAGE) 30-day option implied volatility above 80
-
Sage Therapeutics (SAGE) PT Lowered to $9 at Piper Sandler Following Coverage Transfer
-
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm
-
Sage Therapeutics (SAGE) PT Lowered to $6 at Mizuho
-
Sage Therapeutics (SAGE) PT Lowered to $9 at TD Cowen
-
RBC Capital Upgrades Sage Therapeutics (SAGE) to Sector Perform
-
SAGE Therapeutics (SAGE) Reports Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor
-
Sage Therapeutics (SAGE) PT Lowered to $10 at Mizuho
-
Sage Therapeutics (SAGE) PT Lowered to $26 at Piper Sandler
-
Sage Therapeutics (SAGE) PT Lowered to $14 at Scotiabank
-
Sage Therapeutics (SAGE) PT Lowered to $14 at H.C. Wainwright
-
SAGE Therapeutics (SAGE) Tops Q3 EPS by 1c
-
SAGE Therapeutics (SAGE) Announces Strategic Reorganization to Prioritize ZURZUVAE Commercialization and Focus its Development Portfolio
-
Raymond James Resumes Sage Therapeutics (SAGE) at Market Perform
-
Scotiabank Reiterates Sector Outperform Rating on Sage Therapeutics (SAGE)
-
Sage Therapeutics (SAGE) PT Lowered to $9 at Baird
-
Sage Therapeutics (SAGE) PT Lowered to $9 at Oppenheimer
-
Sage Therapeutics (SAGE) Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor
-
RBC Downgrades Sage (SAGE) to Underperform, 'Too Much Riding On Dalza Huntington's Readout Our Analysis Shows Is High Risk'
-
SAGE Therapeutics (SAGE) Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
-
SAGE Therapeutics (SAGE) Files Mixed Shelf
-
Sage Therapeutics (SAGE) PT Lowered to $13 at Truist Securities
-
Increasing unusual call option volume: UMC IAU SAGE ABEV K DLO LUMN GENI ACI
-
Sage Therapeutics (SAGE) PT Lowered to $52 at Piper Sandler
-
Sage Therapeutics (SAGE) PT Lowered to $12 at Mizuho
-
Sage Therapeutics (SAGE) PT Lowered to $15 at Stifel
-
SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c
-
TD Cowen Downgrades Sage Therapeutics (SAGE) to Hold
-
Sage Therapeutics (SAGE) PT Lowered to $17 at Scotiabank
-
Sage Therapeutics (SAGE) PT Lowered to $13 at Baird
-
Sage Therapeutics (SAGE) PT Lowered to $13 at Mizuho
-
JPMorgan Downgrades Sage Therapeutics (SAGE) to Neutral
-
Sage Therapeutics stock sinks after drug study failed
-
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
-
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
-
Sage Therapeutics (SAGE) PT Lowered to $16 at Mizuho

